Fiche centre
Hopital Gabriel Montpied
Clermont-Ferrand — France
Essais liés4clinical trials
VilleClermont-Ferrandlocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03900221
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Prasinezumab | Parkinson | Phase 2 | NCT04777331 | PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| RO7046015 | Parkinson | Phase 2 | NCT03100149 | PASADENA — A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| RESPONSE — French Registry for Monitoring Pregnancies for Multiple Sclerosis | SEP | À vérifier | NCT03900221 | RESPONSE — French Registry for Monitoring Pregnancies for Multiple Sclerosis | RECRUITING |
| Rimegepant 75mg daily dosing | Migraine | Phase 4 | NCT05217927 | Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens | COMPLETED |